| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
100,828 |
93,045 |
$7.99M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
61,777 |
55,012 |
$5.42M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
30,754 |
9,784 |
$3.88M |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
10,689 |
10,403 |
$2.44M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
25,162 |
21,734 |
$2.17M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
19,454 |
18,200 |
$1.52M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
18,823 |
6,070 |
$1.36M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
15,776 |
15,111 |
$1.31M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
6,111 |
5,476 |
$1.21M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
15,169 |
5,343 |
$821K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
11,586 |
10,086 |
$785K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
22,242 |
19,317 |
$630K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
4,492 |
4,000 |
$622K |
| 80053 |
Comprehensive metabolic panel |
52,757 |
44,268 |
$588K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
11,488 |
9,667 |
$557K |
| 70450 |
Computed tomography, head or brain; without contrast material |
7,555 |
6,557 |
$493K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
15,343 |
12,452 |
$484K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
5,724 |
4,680 |
$476K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,929 |
6,275 |
$397K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
4,393 |
3,754 |
$375K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
9,293 |
7,905 |
$322K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
2,056 |
1,810 |
$280K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,679 |
4,382 |
$259K |
| 59025 |
Fetal non-stress test |
3,512 |
2,834 |
$247K |
| 97161 |
|
2,233 |
2,053 |
$241K |
| 36415 |
Collection of venous blood by venipuncture |
9,020 |
6,293 |
$237K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
4,184 |
1,421 |
$236K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
2,532 |
1,003 |
$217K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
6,553 |
5,639 |
$213K |
| 01999 |
|
2,613 |
2,335 |
$193K |
| 81003 |
|
15,260 |
13,821 |
$187K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
11,479 |
8,742 |
$182K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
2,263 |
1,925 |
$173K |
| 87070 |
|
3,763 |
3,413 |
$165K |
| 71046 |
Radiologic examination, chest; 2 views |
8,192 |
7,588 |
$153K |
| 92523 |
|
1,052 |
1,035 |
$148K |
| 81025 |
|
11,067 |
9,914 |
$141K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,582 |
1,829 |
$134K |
| 81001 |
|
32,808 |
29,082 |
$131K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,542 |
1,434 |
$119K |
| G0378 |
Hospital observation service, per hour |
11,300 |
5,708 |
$113K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,352 |
5,466 |
$103K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
9,033 |
8,394 |
$91K |
| 73610 |
|
1,830 |
1,718 |
$87K |
| 86901 |
|
3,438 |
2,997 |
$85K |
| 71045 |
Radiologic examination, chest; single view |
21,419 |
18,560 |
$82K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,862 |
1,604 |
$79K |
| 87807 |
|
828 |
805 |
$76K |
| 73630 |
|
2,067 |
1,860 |
$70K |
| 73130 |
|
1,795 |
1,634 |
$69K |
| 97165 |
|
615 |
600 |
$68K |
| 82947 |
|
9,143 |
5,179 |
$67K |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
829 |
798 |
$62K |
| 97162 |
|
1,518 |
1,326 |
$61K |
| 12011 |
|
679 |
651 |
$58K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
157 |
146 |
$56K |
| 12001 |
|
790 |
739 |
$54K |
| 73562 |
|
1,907 |
1,677 |
$50K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
60,567 |
49,648 |
$47K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
697 |
630 |
$45K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,169 |
728 |
$41K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
2,327 |
2,125 |
$40K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
165 |
164 |
$39K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
25,603 |
20,957 |
$39K |
| 73110 |
|
1,304 |
1,188 |
$38K |
| 74018 |
|
2,763 |
2,618 |
$37K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,163 |
3,057 |
$36K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
802 |
686 |
$35K |
| 82962 |
|
1,795 |
749 |
$35K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
2,042 |
1,873 |
$34K |
| 84484 |
|
23,196 |
12,789 |
$33K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,618 |
1,279 |
$32K |
| 84702 |
|
5,410 |
4,307 |
$32K |
| 84112 |
|
537 |
491 |
$32K |
| 96376 |
|
4,418 |
2,427 |
$31K |
| 76801 |
|
3,658 |
2,918 |
$31K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
2,080 |
1,923 |
$30K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
246 |
197 |
$30K |
| 73030 |
|
1,381 |
1,185 |
$27K |
| 93458 |
|
165 |
133 |
$27K |
| 70486 |
|
293 |
265 |
$24K |
| 72131 |
|
579 |
492 |
$24K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,233 |
1,157 |
$24K |
| 84703 |
|
10,285 |
9,315 |
$23K |
| 73080 |
|
688 |
639 |
$23K |
| 85610 |
|
7,331 |
5,865 |
$21K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,836 |
2,630 |
$21K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
13,485 |
10,738 |
$20K |
| 85027 |
|
6,132 |
4,604 |
$20K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
283 |
251 |
$20K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
362 |
341 |
$18K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
16,861 |
11,890 |
$17K |
| 73090 |
|
502 |
457 |
$17K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
4,048 |
3,303 |
$16K |
| 72100 |
|
1,361 |
1,214 |
$16K |
| 82247 |
|
1,483 |
1,079 |
$16K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
411 |
387 |
$15K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
3,113 |
2,531 |
$15K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
7,029 |
6,507 |
$12K |
| 70491 |
|
38 |
36 |
$12K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
1,187 |
638 |
$12K |
| J2785 |
Injection, regadenoson, 0.1 mg |
120 |
88 |
$12K |
| C1769 |
Guide wire |
1,176 |
894 |
$11K |
| 85730 |
|
5,321 |
4,291 |
$11K |
| 83735 |
|
6,423 |
4,818 |
$11K |
| 93971 |
|
1,248 |
1,058 |
$11K |
| 80076 |
|
253 |
219 |
$11K |
| 87400 |
|
288 |
267 |
$11K |
| 72040 |
|
262 |
249 |
$11K |
| 87210 |
|
1,481 |
1,395 |
$10K |
| 97113 |
|
49 |
13 |
$9K |
| 80050 |
General health panel |
895 |
861 |
$9K |
| 12002 |
|
161 |
150 |
$9K |
| 97163 |
|
235 |
212 |
$9K |
| 80061 |
Lipid panel |
2,754 |
2,241 |
$9K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
7,741 |
7,571 |
$8K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
705 |
520 |
$8K |
| 87077 |
|
2,347 |
1,890 |
$8K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
768 |
598 |
$8K |
| 97166 |
|
103 |
93 |
$8K |
| 71250 |
|
140 |
111 |
$8K |
| 73140 |
|
354 |
331 |
$8K |
| 73590 |
|
366 |
316 |
$7K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,624 |
1,189 |
$7K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
3,407 |
2,697 |
$7K |
| 70498 |
|
17 |
14 |
$7K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
737 |
445 |
$7K |
| 83690 |
|
13,967 |
12,149 |
$6K |
| 99152 |
|
837 |
680 |
$6K |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,584 |
2,695 |
$5K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
3,072 |
2,138 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
10,109 |
8,655 |
$5K |
| 73502 |
|
383 |
344 |
$5K |
| 83880 |
|
3,189 |
2,608 |
$5K |
| 97116 |
|
345 |
139 |
$5K |
| 82803 |
|
512 |
403 |
$5K |
| 76506 |
|
57 |
56 |
$5K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
451 |
184 |
$4K |
| 93017 |
|
271 |
217 |
$4K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
213 |
183 |
$4K |
| 93970 |
|
341 |
304 |
$4K |
| 82553 |
|
248 |
123 |
$4K |
| 82550 |
|
912 |
662 |
$4K |
| 86140 |
|
3,698 |
3,371 |
$4K |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
314 |
224 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,450 |
2,066 |
$4K |
| 99153 |
Mod sedat endo service >5yrs |
192 |
154 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
5,778 |
4,694 |
$3K |
| J2704 |
Injection, propofol, 10 mg |
765 |
619 |
$3K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
133 |
104 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
5,305 |
3,912 |
$3K |
| 87430 |
|
355 |
343 |
$3K |
| 82248 |
|
943 |
751 |
$3K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
753 |
610 |
$3K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,977 |
1,553 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,551 |
1,316 |
$3K |
| 10060 |
|
116 |
109 |
$2K |
| 87040 |
|
4,253 |
2,678 |
$2K |
| 85379 |
|
2,789 |
2,454 |
$2K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
90 |
72 |
$2K |
| 84295 |
|
501 |
426 |
$2K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
52 |
39 |
$2K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
41 |
33 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
24 |
20 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,477 |
2,274 |
$2K |
| 76870 |
|
90 |
84 |
$2K |
| 86900 |
|
3,410 |
2,977 |
$2K |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,769 |
876 |
$2K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
45 |
14 |
$2K |
| 87186 |
|
2,516 |
2,114 |
$2K |
| 97150 |
Therapeutic procedure(s), group (2 or more individuals) |
503 |
235 |
$2K |
| 76775 |
|
135 |
121 |
$2K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
872 |
735 |
$2K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
28 |
24 |
$2K |
| 83605 |
|
3,904 |
3,096 |
$2K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,032 |
918 |
$2K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
79 |
61 |
$1K |
| 88304 |
|
210 |
184 |
$1K |
| 86850 |
|
1,596 |
1,354 |
$1K |
| 74019 |
|
103 |
103 |
$1K |
| C9113 |
Injection, pantoprazole sodium, per vial |
801 |
558 |
$1K |
| 29125 |
|
191 |
178 |
$1K |
| J2060 |
Injection, lorazepam, 2 mg |
1,537 |
1,214 |
$1K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
2,028 |
1,715 |
$1K |
| 84132 |
|
709 |
593 |
$1K |
| 82731 |
|
29 |
25 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,231 |
1,056 |
$952.05 |
| 88342 |
|
170 |
140 |
$876.19 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
660 |
591 |
$760.55 |
| 90714 |
|
321 |
269 |
$706.14 |
| 97535 |
Self-care/home management training, each 15 minutes |
235 |
177 |
$649.36 |
| 99218 |
|
104 |
96 |
$607.69 |
| 82565 |
|
684 |
581 |
$602.02 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
159 |
156 |
$577.55 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
165 |
101 |
$573.89 |
| 84156 |
|
248 |
205 |
$569.76 |
| 84439 |
|
108 |
97 |
$559.09 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
129 |
100 |
$539.31 |
| 93880 |
|
48 |
38 |
$498.85 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
283 |
174 |
$450.65 |
| 85652 |
|
743 |
667 |
$448.75 |
| 82077 |
|
1,350 |
1,141 |
$410.78 |
| 86780 |
|
130 |
117 |
$372.49 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
976 |
814 |
$336.09 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
13 |
13 |
$322.01 |
| 84145 |
|
500 |
454 |
$310.19 |
| J7121 |
5% dextrose in lactated ringers infusion, up to 1000 cc |
129 |
111 |
$262.94 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
30 |
27 |
$191.16 |
| 93976 |
|
15 |
14 |
$190.31 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
632 |
312 |
$175.73 |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
144 |
134 |
$173.54 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
152 |
76 |
$162.87 |
| 87205 |
|
82 |
66 |
$134.96 |
| 84550 |
|
91 |
77 |
$126.30 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
507 |
455 |
$121.92 |
| 82150 |
|
303 |
280 |
$88.88 |
| 84520 |
|
481 |
409 |
$80.80 |
| 82435 |
|
456 |
386 |
$80.80 |
| 82607 |
|
275 |
242 |
$67.03 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
14 |
13 |
$63.72 |
| 76830 |
Ultrasound, transvaginal |
14 |
14 |
$63.72 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
463 |
374 |
$59.73 |
| 82746 |
|
129 |
107 |
$58.64 |
| 90715 |
|
256 |
234 |
$57.81 |
| 96367 |
|
80 |
64 |
$52.36 |
| J1630 |
Injection, haloperidol, up to 5 mg |
660 |
529 |
$41.05 |
| 94760 |
|
357 |
264 |
$40.31 |
| 84030 |
|
12 |
12 |
$37.20 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
227 |
159 |
$22.77 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
263 |
122 |
$17.03 |
| 82330 |
|
505 |
436 |
$13.33 |
| Q3014 |
Telehealth originating site facility fee |
366 |
131 |
$10.66 |
| 82810 |
|
12 |
12 |
$7.35 |
| 85014 |
|
356 |
305 |
$4.10 |
| 82570 |
|
306 |
259 |
$3.14 |
| 85007 |
|
91 |
84 |
$0.00 |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
222 |
173 |
$0.00 |
| 80179 |
|
695 |
600 |
$0.00 |
| 94664 |
|
65 |
43 |
$0.00 |
| J3105 |
Injection, terbutaline sulfate, up to 1 mg |
31 |
28 |
$0.00 |
| 80143 |
|
113 |
108 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
697 |
655 |
$0.00 |
| J3486 |
Injection, ziprasidone mesylate, 10 mg |
14 |
13 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
61 |
53 |
$0.00 |
| 84100 |
|
83 |
73 |
$0.00 |
| 82009 |
|
31 |
26 |
$0.00 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
20 |
13 |
$0.00 |
| 83540 |
|
14 |
12 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
23 |
12 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
18 |
15 |
$0.00 |
| J1815 |
Injection, insulin, per 5 units |
372 |
148 |
$0.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
40 |
24 |
$0.00 |
| 72128 |
|
14 |
12 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
163 |
104 |
$0.00 |
| 96368 |
|
16 |
14 |
$0.00 |
| 94762 |
|
83 |
61 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
29 |
24 |
$0.00 |
| 86308 |
|
40 |
40 |
$0.00 |
| 70496 |
|
15 |
12 |
$0.00 |
| 82728 |
|
15 |
14 |
$0.00 |
| 87081 |
|
72 |
67 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
30 |
29 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
59 |
26 |
$0.00 |
| 74022 |
|
13 |
12 |
$0.00 |
| 71101 |
|
14 |
12 |
$0.00 |
| J3490 |
Unclassified drugs |
61 |
32 |
$0.00 |